

Donor-Derived Cell-free DNA for Heart Transplant Rejection

- I. The use of peripheral blood measurement of donor-derived cell-free DNA in the management of patients after heart transplantation is considered **medically necessary** when:
 - A. The member has undergone a heart transplant, **AND**
 - B. Peripheral blood measurement of donor-derived cell-free DNA testing has not been performed in the past twelve months.
- II. The use of peripheral blood measurement of donor-derived cell-free DNA in the management of patients after heart transplantation is considered **investigational** for all other indications.

REFERENCES

1. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2023;42(5):e1-e141.
doi:10.1016/j.healun.2022.10.015
2. ASTS Statement on donor-derived cell-free DNA (dd-cf-DNA). Published online March 6, 2023, Updated October 2024. American Society of Transplant Surgeons.
[https://www.astsonline.org/docs/default-source/position-statements/asts-statement-on-donor-derived-cell-free-dna-\(dd-cfdna\)---updated-oct.-2024.pdf](https://www.astsonline.org/docs/default-source/position-statements/asts-statement-on-donor-derived-cell-free-dna-(dd-cfdna)---updated-oct.-2024.pdf)